Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Long-Term Debt Repayments: 2021-2022

Historic Long-Term Debt Repayments for Cidara Therapeutics (CDTX) over the last 2 years, with Sep 2022 value amounting to $371,000.

  • Cidara Therapeutics' Long-Term Debt Repayments fell 66.61% to $371,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2022, which is 41.65% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Long-Term Debt Repayments of $371,000 as of Q3 2022, which was down 66.61% from $1.1 million recorded in Q2 2022.
  • In the past 5 years, Cidara Therapeutics' Long-Term Debt Repayments ranged from a high of $1.1 million in Q1 2021 and a low of $371,000 during Q3 2022.
  • Its 2-year average for Long-Term Debt Repayments is $1.0 million, with a median of $1.1 million in 2022.
  • Data for Cidara Therapeutics' Long-Term Debt Repayments shows a maximum YoY tumbled of 66.61% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Cidara Therapeutics' Long-Term Debt Repayments stood at $1.1 million in 2021, then crashed by 66.61% to $371,000 in 2022.
  • Its last three reported values are $371,000 in Q3 2022, $1.1 million for Q2 2022, and $1.1 million during Q1 2022.